The stock surged 15% after a major mutual fund acquired a 2.91% stake via a bulk deal, even as another investor trimmed holdings. Strong Q1 growth in digital dentistry, exports, and scanners, alongside confident FY26 guidance, underscores long-term expansion potential.
The shares of the medical equipment manufacturer jumped 15 percent in today’s trading session after ICICI Prudential mutual funds acquired 1,600,959 equity shares via Bulk Deal.
With a market capitalization of Rs 1,822.00 crore, the shares of Laxmi Dental Ltd were trading at Rs 333.00 per share, increasing around 9.81 percent as compared to the previous closing price of Rs 303.25 apiece.
Block Deal
The shares of Laxmi Dental Ltd have seen bullish movement after ICICI Prudential MF acquired 1,600,959 shares, which is equivalent 2.91 percent stake in the company, at an average price of Rs 303 per share. This transaction is valued at Rs 48.5 crore.
However, Abu Dhabi Investment Authority (ADIA) sold 5.58 lakh shares each in Laxmi Dental at Rs 303.01 per share, amounting to a 2.03 percent stake valued at Rs 16.91 crore. Additionally, as of June 2025, ADIA held a 3.18 percent stake in the company.
The company delivered mixed Q1FY26 results, with revenue rising 10 percent to Rs 65.60 crore from Rs 59.67 crore in Q1FY25, signaling healthy top-line growth. However, net profit slumped 51 percent to Rs 8.33 crore versus Rs 16.85 crore, reflecting margin pressures, higher costs, or one-time expenses, indicating profitability challenges despite improving sales momentum.
The company’s Q1FY26 segmental performance shows balanced growth. The dental lab business rose 8 percent YoY, forming 59 percent of revenues. Aligner solutions surged 18 percent, contributing 28 percent, supported by B2B and branded sales with celebrity endorsement. Scanner sales jumped 26 percent, with 200 units sold versus 80 last year, while Kids-e-Dental delivered Rs 4.4 crore, targeting 20–25 percent growth ahead.
Also read: Pharma stock in focus after its subsidiary launches FDA-approved veterinary drugs in US
India continues to drive core growth, while exports contribute 20 percent of revenue across the US, Europe, APAC, and the Middle East. Despite US tariff hikes to 25 percent, management expects minimal margin impact (0.5–1 percent) by passing costs to customers. With presence in 95–100 countries, regulatory clearances remain key to global expansion.
Management remains upbeat, guiding for 20–25 percent revenue growth in FY26, led by digital dentistry, AI adoption, and strong brand investments. Strategic focus is on global expansion and margin preservation over aggressive pricing. With the dental industry undergoing rapid digital and AI-led transformation, the company positions itself as a frontrunner in this evolving landscape.
Laxmi Dental Limited is a key player in the dental healthcare industry, offering dental laboratory services and advanced digital solutions like aligners and scanners. The company is strategically focused on driving the adoption of digital dentistry through innovation, efficiency, and global market expansion.
Written by Abhishek Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
